These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 11143484)

  • 1. Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
    Ratanatharathorn V; Sirachainan E; Jirajarus M; Sirilerttrakul S
    J Med Assoc Thai; 2000 Oct; 83(10):1187-95. PubMed ID: 11143484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
    Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
    Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
    Benavides M; García-Alfonso P; Cobo M; Muñoz-Martín A; Gil-Calle S; Carabantes F; Villar E; Graupera J; Balcells M; Pérez-Manga G
    Med Oncol; 2004; 21(3):255-62. PubMed ID: 15456953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
    Van Cutsem E; Cunningham D; Ten Bokkel Huinink WW; Punt CJ; Alexopoulos CG; Dirix L; Symann M; Blijham GH; Cholet P; Fillet G; Van Groeningen C; Vannetzel JM; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
    Eur J Cancer; 1999 Jan; 35(1):54-9. PubMed ID: 10211088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer].
    Nishina T; Hyodo I; Moriwaki T; Kajiwara T; Tsuzuki T; Hirao K; Tubouchi E; Nasu J; Hirasaki S; Masumoto T; Kubo Y; Kurita A
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1361-4. PubMed ID: 15446557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
    Garufi C; Dogliotti L; D'Attino RM; Tampellini M; Aschelter AM; Pugliese P; Perrone M; Nisticó C; Comis S; Terzoli E
    Cancer; 2001 Feb; 91(4):712-20. PubMed ID: 11241238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.
    Michael M; Hedley D; Oza A; Feld R; Pintilie M; Goel R; Maroun J; Jolivet J; Fields A; Lee IM; Moore MJ
    Clin Colorectal Cancer; 2002 Aug; 2(2):93-101. PubMed ID: 12453323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
    Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
    J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
    Antón A; Aranda E; Carrato A; Marcuello E; Massutti B; Cervantes A; Abad A; Sastre J; Fenández-Martos C; Gallén M; Díaz-Rubio E; Huarte L; Balcells M;
    Methods Find Exp Clin Pharmacol; 2003 Oct; 25(8):639-43. PubMed ID: 14671682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
    Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C
    Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
    Pitot HC; Wender DB; O'Connell MJ; Schroeder G; Goldberg RM; Rubin J; Mailliard JA; Knost JA; Ghosh C; Kirschling RJ; Levitt R; Windschitl HE
    J Clin Oncol; 1997 Aug; 15(8):2910-9. PubMed ID: 9256135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer.
    Cassinello J; López-Alvarez P; Martínez-Guisado A; Valladares M; Huidobro G; López R; Bohn U; Sevilla I; Ballesteros P; Jorge M; Pérez-Carrión R; Fernández JL; Dorta J
    Med Oncol; 2003; 20(1):37-43. PubMed ID: 12665683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.
    Saigi E; Salut A; Campos JM; Losa F; Manzano H; Batiste-Alentorn E; Acusa A; Vélez de Mendizabal E; Guasch I; Antón I;
    Anticancer Drugs; 2004 Oct; 15(9):835-41. PubMed ID: 15457123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan in 5-fluorouracil-refractory colorectal cancer.
    Danesi R; Di Paolo A
    Clin Colorectal Cancer; 2002 Aug; 2(2):102-3. PubMed ID: 12453324
    [No Abstract]   [Full Text] [Related]  

  • 18. [Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
    Sasaki K; Takasaka H; Kawasaki H; Matsunaga T; Nakagawa N; Shibata K; Yabana T; Yasojima T; Furuhata T; Hata F; Hirata K
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):915-9. PubMed ID: 10897221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of metastatic liver tumor of colorectal cancer responding to low-dose CPT-11 chemotherapy].
    Funahashi K; Miki T; Koike J; Washizawa N; Shibata Y; Matsumoto H; Tokuyama T; Ryu M; Shiokawa H; Goto T; Teramoto T
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):419-21. PubMed ID: 12669404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.
    Ogata Y; Sasatomi T; Mori S; Matono K; Ishibashi N; Akagi Y; Fukushima T; Murakami H; Ushijima M; Shirouzu K
    Anticancer Res; 2007; 27(4C):2605-11. PubMed ID: 17695422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.